🚀 VC round data is live in beta, check it out!
COSMOS Pharmaceutical Valuation Multiples
Discover revenue and EBITDA valuation multiples for COSMOS Pharmaceutical and similar public comparables like Nahdi Medical, CR Pharmaceutical, DaShenLin Pharmaceutical, Jointown Pharmaceutical and more.
COSMOS Pharmaceutical Overview
About COSMOS Pharmaceutical
COSMOS Pharmaceutical Corp manages retail drugstores in Japan. The company emphasizes convenience regarding its product selection, which includes medical products, health and beauty aids, personal-care items, discount cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, alcoholic beverages, tobacco, insect repellent, and miscellaneous everyday consumables. The majority of the company’s revenue is derived from common grocery sales. It also operates a private grocery brand called ON 365.
Founded
1983
HQ
Employees
28.8K
Website
Sectors
Financials (LTM)
EV
$3B
COSMOS Pharmaceutical Financials
COSMOS Pharmaceutical reported last 12-month revenue of $7B and EBITDA of $417M.
In the same LTM period, COSMOS Pharmaceutical generated $1B in gross profit, $417M in EBITDA, and $201M in net income.
Revenue (LTM)
COSMOS Pharmaceutical P&L
In the most recent fiscal year, COSMOS Pharmaceutical reported revenue of $7B and EBITDA of $423M.
COSMOS Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $7B | XXX | $7B | XXX | XXX | XXX |
| Gross Profit | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Margin | 22% | XXX | 20% | XXX | XXX | XXX |
| EBITDA | $417M | XXX | $423M | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | 6% | XXX | XXX | XXX |
| EBIT Margin | 4% | XXX | 4% | XXX | XXX | XXX |
| Net Profit | $201M | XXX | $210M | XXX | XXX | XXX |
| Net Margin | 3% | XXX | 3% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
COSMOS Pharmaceutical Stock Performance
COSMOS Pharmaceutical has current market cap of $3B, and enterprise value of $3B.
Market Cap Evolution
COSMOS Pharmaceutical's stock price is $43.67.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $3B | 0.1% | XXX | XXX | XXX | $2.65 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCOSMOS Pharmaceutical Valuation Multiples
COSMOS Pharmaceutical trades at 0.5x EV/Revenue multiple, and 8.3x EV/EBITDA.
EV / Revenue (LTM)
COSMOS Pharmaceutical Financial Valuation Multiples
As of March 19, 2026, COSMOS Pharmaceutical has market cap of $3B and EV of $3B.
Equity research analysts estimate COSMOS Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
COSMOS Pharmaceutical has a P/E ratio of 17.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 0.5x | XXX | 0.5x | XXX | XXX | XXX |
| EV/EBITDA | 8.3x | XXX | 8.1x | XXX | XXX | XXX |
| EV/EBIT | 13.0x | XXX | 12.6x | XXX | XXX | XXX |
| EV/Gross Profit | 2.3x | XXX | 2.6x | XXX | XXX | XXX |
| P/E | 17.2x | XXX | 16.5x | XXX | XXX | XXX |
| EV/FCF | 119.3x | XXX | (636.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified COSMOS Pharmaceutical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
COSMOS Pharmaceutical Margins & Growth Rates
COSMOS Pharmaceutical's revenue in the last 12 month grew by 5%.
COSMOS Pharmaceutical's revenue per employee in the last FY averaged $0.2M.
COSMOS Pharmaceutical's rule of 40 is 11% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
COSMOS Pharmaceutical's rule of X is 19% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
COSMOS Pharmaceutical Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | (1%) | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | (2%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 11% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 19% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 0% | XXX | — | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 16% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
COSMOS Pharmaceutical Public Comps
See public comps and valuation multiples for other Pharmacies comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Nahdi Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| CR Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| DaShenLin Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Jointown Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Sundrug | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
COSMOS Pharmaceutical M&A Activity
COSMOS Pharmaceutical acquired XXX companies to date.
Last acquisition by COSMOS Pharmaceutical was on XXXXXXXX, XXXXX. COSMOS Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by COSMOS Pharmaceutical
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCOSMOS Pharmaceutical Investment Activity
COSMOS Pharmaceutical invested in XXX companies to date.
COSMOS Pharmaceutical made its latest investment on XXXXXXXX, XXXXX. COSMOS Pharmaceutical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by COSMOS Pharmaceutical
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout COSMOS Pharmaceutical
| When was COSMOS Pharmaceutical founded? | COSMOS Pharmaceutical was founded in 1983. |
| Where is COSMOS Pharmaceutical headquartered? | COSMOS Pharmaceutical is headquartered in Japan. |
| How many employees does COSMOS Pharmaceutical have? | As of today, COSMOS Pharmaceutical has over 28K employees. |
| Is COSMOS Pharmaceutical publicly listed? | Yes, COSMOS Pharmaceutical is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of COSMOS Pharmaceutical? | COSMOS Pharmaceutical trades under 3349 ticker. |
| When did COSMOS Pharmaceutical go public? | COSMOS Pharmaceutical went public in 2004. |
| Who are competitors of COSMOS Pharmaceutical? | COSMOS Pharmaceutical main competitors are Nahdi Medical, CR Pharmaceutical, DaShenLin Pharmaceutical, Jointown Pharmaceutical. |
| What is the current market cap of COSMOS Pharmaceutical? | COSMOS Pharmaceutical's current market cap is $3B. |
| What is the current revenue of COSMOS Pharmaceutical? | COSMOS Pharmaceutical's last 12 months revenue is $7B. |
| What is the current revenue growth of COSMOS Pharmaceutical? | COSMOS Pharmaceutical revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of COSMOS Pharmaceutical? | Current revenue multiple of COSMOS Pharmaceutical is 0.5x. |
| Is COSMOS Pharmaceutical profitable? | Yes, COSMOS Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of COSMOS Pharmaceutical? | COSMOS Pharmaceutical's last 12 months EBITDA is $417M. |
| What is COSMOS Pharmaceutical's EBITDA margin? | COSMOS Pharmaceutical's last 12 months EBITDA margin is 6%. |
| What is the current EV/EBITDA multiple of COSMOS Pharmaceutical? | Current EBITDA multiple of COSMOS Pharmaceutical is 8.3x. |
| What is the current FCF of COSMOS Pharmaceutical? | COSMOS Pharmaceutical's last 12 months FCF is $29M. |
| What is COSMOS Pharmaceutical's FCF margin? | COSMOS Pharmaceutical's last 12 months FCF margin is 0%. |
| What is the current EV/FCF multiple of COSMOS Pharmaceutical? | Current FCF multiple of COSMOS Pharmaceutical is 119.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.